Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial

<b>Rationale:</b> Prior evidence suggests that endothelial glycocalyx degradation contributes to sepsis pathogenesis and is potentially worsened by intravenous fluid resuscitation. <b>Objectives:</b> To assess <i>1</i>) the association of endothelial glycocalyx degradation with sepsis mortality, <i>2</i>) the impact of a randomly assigned liberal versus restrictive intravenous fluid resuscitation strategy on endothelial glycocalyx degradation, and <i>3</i>) whether there is a differential treatment effect for mortality based on baseline endothelial glycocalyx degradation. <b>Methods:</b> We used an enriched sampling strategy to define a cohort of 574 patients enrolled in the CLOVERS (Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis) trial, which compared liberal versus restrictive intravenous fluid resuscitation strategies. We used mass spectrometry to quantify plasma heparan sulfate as the primary measure of endothelial glycocalyx degradation. Plasma syndecan-1, quantified by enzyme-linked immunoassay, served as a clinically feasible complementary index of endothelial glycocalyx degradation. The primary outcome was 90-day all-cause mortality. <b>Results:</b> There was an association between baseline heparan sulfate level and mortality, with increasing mortality by baseline heparan sulfate tertile: lower tertile, 9.9% (95% confidence interval, 7.0-12.7%); middle tertile, 20.4% (15.6-25.0%); and upper tertile, 44.2% (35.6-51.6%) (<i>P</i> < 0.001; log-rank test), with an adjusted hazard ratio for interquartile range change in heparan sulfate of 3.12 (95% confidence interval, 2.18-4.46). We observed no effect of assigned fluid resuscitation strategy on endothelial glycocalyx degradation 24 hours after randomization. We observed no evidence of differential treatment effect of fluid resuscitation strategy based on baseline plasma heparan sulfate for 90-day mortality. Similar findings were observed using plasma syndecan-1 as an index of endothelial glycocalyx degradation. <b>Conclusions:</b> Endothelial glycocalyx degradation is a strong predictor of mortality in sepsis. Fluid resuscitation strategy had no impact on endothelial glycocalyx degradation, and there was no evidence for a differential effect of resuscitation strategy by baseline levels of endothelial glycocalyx degradation. Clinical trial registered with www.clinicaltrials.gov (NCT03434028).

Authors

Institutions

Publication Details

Journal
Annals of the American Thoracic Society
Published
2025-05-02
DOI
https://doi.org/10.1513/annalsats.202501-012oc
Citations
7
Primary Topic
Trauma, Hemostasis, Coagulopathy, Resuscitation
Type
article
Field-Weighted Citation Impact
10.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial

Sarah A McMurty, Christopher John Lindsell, Max S Kravitz, Ryan C. Burke et al.
7 citations
Annals of the American Thoracic Society
Trauma, Hemostasis, Coagulopathy, Resuscitation
10.82
article

Endothelial Glycocalyx Degradation in Sepsis: Analysis of the Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis (CLOVERS) Trial, a Multicenter, Phase 3, Randomized Trial

Sarah A McMurty, Christopher John Lindsell, Max S Kravitz, Ryan C. Burke, Kaori Oshima, Wesley H. Self, Nathan Ivan Shapiro, Angelo D’Alessandro, Bailu Yan, Jonathan S. Schildcrout, Daniel Stephenson, Kirk C. Hansen, Eric P. Schmidt, Chiara Di Gravio, Ivor S. Douglas, Aaron Issaian, Lisa M Levoir
article en
7 citations

Abstract

<b>Rationale:</b> Prior evidence suggests that endothelial glycocalyx degradation contributes to sepsis pathogenesis and is potentially worsened by intravenous fluid resuscitation. <b>Objectives:</b> To assess <i>1</i>) the association of endothelial glycocalyx degradation with sepsis mortality, <i>2</i>) the impact of a randomly assigned liberal versus restrictive intravenous fluid resuscitation strategy on endothelial glycocalyx degradation, and <i>3</i>) whether there is a differential treatment effect for mortality based on baseline endothelial glycocalyx degradation. <b>Methods:</b> We used an enriched sampling strategy to define a cohort of 574 patients enrolled in the CLOVERS (Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis) trial, which compared liberal versus restrictive intravenous fluid resuscitation strategies. We used mass spectrometry to quantify plasma heparan sulfate as the primary measure of endothelial glycocalyx degradation. Plasma syndecan-1, quantified by enzyme-linked immunoassay, served as a clinically feasible complementary index of endothelial glycocalyx degradation. The primary outcome was 90-day all-cause mortality. <b>Results:</b> There was an association between baseline heparan sulfate level and mortality, with increasing mortality by baseline heparan sulfate tertile: lower tertile, 9.9% (95% confidence interval, 7.0-12.7%); middle tertile, 20.4% (15.6-25.0%); and upper tertile, 44.2% (35.6-51.6%) (<i>P</i> < 0.001; log-rank test), with an adjusted hazard ratio for interquartile range change in heparan sulfate of 3.12 (95% confidence interval, 2.18-4.46). We observed no effect of assigned fluid resuscitation strategy on endothelial glycocalyx degradation 24 hours after randomization. We observed no evidence of differential treatment effect of fluid resuscitation strategy based on baseline plasma heparan sulfate for 90-day mortality. Similar findings were observed using plasma syndecan-1 as an index of endothelial glycocalyx degradation. <b>Conclusions:</b> Endothelial glycocalyx degradation is a strong predictor of mortality in sepsis. Fluid resuscitation strategy had no impact on endothelial glycocalyx degradation, and there was no evidence for a differential effect of resuscitation strategy by baseline levels of endothelial glycocalyx degradation. Clinical trial registered with www.clinicaltrials.gov (NCT03434028).

Annals of the American Thoracic SocietyVol. 22(9)
Beth Israel Deaconess Medical Center (US), Harvard University (US), Duke University (US), Denver Health Medical Center (US), Massachusetts General Hospital (US), Duke Medical Center (US), University of Colorado Anschutz Medical Campus (US), Vanderbilt University Medical Center (US), University of Colorado Denver (US)
Zero hunger
Openalex Percentile: Top 1%
Trauma, Hemostasis, Coagulopathy, Resuscitation
10.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.